TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018. (Source: Reuters: Health)


Read full article on medworm.com